This company listing is no longer active
McKesson Europe Valuation
Is CLS1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CLS1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CLS1 (€24.4) is trading above our estimate of fair value (€17.47)
Significantly Below Fair Value: CLS1 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CLS1?
Other financial metrics that can be useful for relative valuation.
| What is CLS1's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | €4.96b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 29.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CLS1's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.5x | ||
ILM1 Medios | 0.2x | 6.5% | €384.2m |
HAEK HAEMATO | 0.3x | 4.4% | €91.0m |
SYAB SYNLAB | 0.9x | 4.4% | €2.4b |
FME Fresenius Medical Care | 0.5x | 3.5% | €10.7b |
CLS1 McKesson Europe | 0.5x | n/a | €5.0b |
Price-To-Sales vs Peers: CLS1 is expensive based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.5x).
Price to Earnings Ratio vs Industry
How does CLS1's PE Ratio compare vs other companies in the DE Healthcare Industry?
Price-To-Sales vs Industry: CLS1 is good value based on its Price-To-Sales Ratio (0.5x) compared to the European Healthcare industry average (0.7x)
Price to Sales Ratio vs Fair Ratio
What is CLS1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CLS1's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.